Achilles Therapeutics Plc. (ACHL), Tuesday announced that the company has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca Plc. (AZN) for $12 million.
Additionally, AstraZeneca will also sponsor Achilles Material Acquisition Platform, a proprietary network donor that has collected tumor tissue and blood from nearly 300 cancer patients.
Moreover, the clinical-stage biopharmaceutical company is planning to reduce the workforce and cut the size of its board as part of its strategic review.
Currently, Achilles's stock is trading at $1.08, up 10.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.